145 related articles for article (PubMed ID: 19731580)
1. Concordance between substance P levels and antiemetic guidelines.
Higa GM; Auber ML; Altaha R; Kurian S; Hobbs G
J Support Oncol; 2009; 7(4):138-42. PubMed ID: 19731580
[TBL] [Abstract][Full Text] [Related]
2. 5-Hydroxyindoleacetic acid and substance P profiles in patients receiving emetogenic chemotherapy.
Higa GM; Auber ML; Altaha R; Piktel D; Kurian S; Hobbs G; Landreth K
J Oncol Pharm Pract; 2006 Dec; 12(4):201-9. PubMed ID: 17156592
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and cost effectiveness of new antiemetic guidelines.
Engstrom C; Hernandez I; Haywood J; Lilenbaum R
Oncol Nurs Forum; 1999 Oct; 26(9):1453-8. PubMed ID: 11064877
[TBL] [Abstract][Full Text] [Related]
4. Clinical practice guidelines on antiemetics in oncology.
Aranda Aguilar E; Constenla Figueiras M; Cortes-Funes H; Diaz-Rubio García E; Gascon Vilaplana P; Guillém V; Martin-Algarra S
Expert Rev Anticancer Ther; 2005 Dec; 5(6):963-72. PubMed ID: 16336087
[TBL] [Abstract][Full Text] [Related]
5. Antiemetics: an update and the MASCC guidelines applied in clinical practice.
Herrstedt J
Nat Clin Pract Oncol; 2008 Jan; 5(1):32-43. PubMed ID: 18097455
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy-induced nausea and vomiting in the treatment of gastrointestinal tumors and secondary prophylaxis with aprepitant.
Abbrederis K; Lorenzen S; Rothling N; Ihbe-Heffinger A; Schuster T; Peschel C; Lordick F
Onkologie; 2009 Feb; 32(1-2):30-4. PubMed ID: 19209016
[TBL] [Abstract][Full Text] [Related]
7. Nausea and vomiting with high-dose chemotherapy and stem cell rescue therapy: a review of antiemetic regimens.
Trigg ME; Inverso DM
Bone Marrow Transplant; 2008 Oct; 42(8):501-6. PubMed ID: 18724391
[TBL] [Abstract][Full Text] [Related]
8. [Croatian guideliness for prevention of chemotherapy induced nausea and vomiting].
Tomek R; Vrdoljak E; Vrbanec D; Nemet D; Matković V; Plestina S; Gugić D; Dintinjana RD; Bolanca A; Samarzija M; Petković M
Lijec Vjesn; 2009; 131(3-4):49-53. PubMed ID: 19514248
[TBL] [Abstract][Full Text] [Related]
9. Anti-emetic therapy in cancer chemotherapy: current status.
Herrstedt J; Dombernowsky P
Basic Clin Pharmacol Toxicol; 2007 Sep; 101(3):143-50. PubMed ID: 17697032
[TBL] [Abstract][Full Text] [Related]
10. [Guidelines for prophylaxis and treatment of chemotherapy-induced nausea and vomiting].
Durand JP; Madelaine I; Scotté F
Bull Cancer; 2009 Oct; 96(10):951-60. PubMed ID: 19734117
[TBL] [Abstract][Full Text] [Related]
11. Intravenous ondansetron plus intravenous dexamethasone with different ondansetron dosing schedules during multiple cycles of cisplatin-based chemotherapy.
Chen PT; Liaw CC
Chang Gung Med J; 2008; 31(2):167-74. PubMed ID: 18567417
[TBL] [Abstract][Full Text] [Related]
12. Do we need new antiemetic guidelines?
Roila F
Support Care Cancer; 2002 Oct; 10(7):517-8. PubMed ID: 12324804
[No Abstract] [Full Text] [Related]
13. Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly patient response.
Massa E; Astara G; Madeddu C; Dessì M; Loi C; Lepori S; Mantovani G
Crit Rev Oncol Hematol; 2009 Apr; 70(1):83-91. PubMed ID: 18723369
[TBL] [Abstract][Full Text] [Related]
14. Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations.
Jordan K; Sippel C; Schmoll HJ
Oncologist; 2007 Sep; 12(9):1143-50. PubMed ID: 17914084
[TBL] [Abstract][Full Text] [Related]
15. Antiemetic therapy in patients treated with cisplatin chemotherapy.
Roila F; Basurto C; Bracarda S; Del Favero A; Tonato M
J Chemother; 1989 Jul; 1(4 Suppl):1281-5. PubMed ID: 16312866
[No Abstract] [Full Text] [Related]
16. Aprepitant--where do we stand in the control of chemotherapy-induced nausea and vomiting?
Sarcev T; Secen N; Zaric B; Milovancev A
J BUON; 2008; 13(3):333-9. PubMed ID: 18979546
[TBL] [Abstract][Full Text] [Related]
17. Antiemetic role of thalidomide in a rat model of cisplatin-induced emesis.
Han ZX; Xu J; Wang HM; Ma J; Sun X; Du XP
Cell Biochem Biophys; 2014 Sep; 70(1):361-5. PubMed ID: 24718779
[TBL] [Abstract][Full Text] [Related]
18. [Neurokinin antagonists as antiemetics].
Heinzl S
Med Monatsschr Pharm; 2003 Oct; 26(10):336-7. PubMed ID: 14587153
[No Abstract] [Full Text] [Related]
19. Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Rev Anticancer Ther; 2008 Nov; 8(11):1733-42. PubMed ID: 18983233
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of maropitant for treatment and prevention of emesis caused by intravenous infusion of cisplatin in dogs.
de la Puente-Redondo VA; Tilt N; Rowan TG; Clemence RG
Am J Vet Res; 2007 Jan; 68(1):48-56. PubMed ID: 17199418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
